Ospedale Valduce, Como   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Como Italy (1853)

Organization Overview

First Clinical Trial
2010
NCT01380938
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Gastroenterology Unit, Ospedale Valduce, Como, Italy. | Gastroenterology Unit, Ospedale Valduce, Como. Italy. | Gastroenterology Unit, Ospedale Valduvce, Como. Italy. | Ospedale Valduce, Gastroenterology Unit, Via Dante 10, 22100, Como, Italy. | Ospedale Valduce S.C. Medicina Interna Sezione di Ematologia

Active Ingredients

Drugs in Phase 4 Trials (2)

scopolamine (transderm scop) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 3 Trials (2)

interferon alpha-2b (Intron-A) (1 trial)

ribavirin (virazole) (1 trial)

Drugs in Phase 2 Trials (3)

cyclophosphamide (cytoxan) (1 trial)

ofatumumab (arzerra) (1 trial)

pentostatin (nipent) (1 trial)

Drugs in Other Trials (1)

polyethylene glycol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoma (Phase 4)

Hepatitis, Chronic (Phase 3)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 8